GSA Capital Partners LLP boosted its stake in Loxo Oncology Inc. (NASDAQ:LOXO) by 13.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 14,440 shares of the biopharmaceutical company’s stock after buying an additional 1,740 shares during the period. GSA Capital Partners LLP owned approximately 0.07% of Loxo Oncology worth $335,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of LOXO. Strs Ohio increased its position in Loxo Oncology by 8.7% in the second quarter. Strs Ohio now owns 11,200 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 900 shares in the last quarter. Swiss National Bank bought a new position in Loxo Oncology during the second quarter valued at $468,000. California State Teachers Retirement System increased its position in Loxo Oncology by 42.9% in the second quarter. California State Teachers Retirement System now owns 27,964 shares of the biopharmaceutical company’s stock valued at $648,000 after buying an additional 8,392 shares in the last quarter. Alps Advisors Inc. increased its position in Loxo Oncology by 39.1% in the second quarter. Alps Advisors Inc. now owns 30,015 shares of the biopharmaceutical company’s stock valued at $696,000 after buying an additional 8,437 shares in the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in Loxo Oncology during the second quarter valued at $918,000. 95.46% of the stock is currently owned by institutional investors and hedge funds.
Shares of Loxo Oncology Inc. (NASDAQ:LOXO) traded down 0.52% during trading on Friday, reaching $26.86. The company’s stock had a trading volume of 64,134 shares. The company’s market capitalization is $581.90 million. Loxo Oncology Inc. has a 1-year low of $16.21 and a 1-year high of $35.00. The stock has a 50 day moving average of $26.89 and a 200-day moving average of $25.13.
Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.14. On average, analysts expect that Loxo Oncology Inc. will post ($2.83) earnings per share for the current year.
Several equities analysts have recently weighed in on LOXO shares. Zacks Investment Research downgraded Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, September 6th. Cowen and Company reissued a “buy” rating on shares of Loxo Oncology in a research report on Wednesday, July 13th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Loxo Oncology currently has an average rating of “Buy” and an average target price of $29.60.
In other Loxo Oncology news, Director Keith T. Flaherty sold 14,500 shares of Loxo Oncology stock in a transaction on Wednesday, September 7th. The stock was sold at an average price of $30.00, for a total value of $435,000.00. Following the sale, the director now owns 45,982 shares in the company, valued at $1,379,460. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David P. Bonita sold 447,857 shares of Loxo Oncology stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $26.96, for a total value of $12,074,224.72. The disclosure for this sale can be found here. 44.40% of the stock is owned by company insiders.
About Loxo Oncology
Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.
Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc. (NASDAQ:LOXO).
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.